Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma

This study has been completed.
Sponsor:
Collaborator:
Genentech
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00113217
First received: June 6, 2005
Last updated: December 2, 2013
Last verified: December 2013
  Purpose

The goal of this clinical research study is to learn if bevacizumab (Avastin®) can control metastatic renal cell carcinoma (RCC). The safety of the treatment will also be studied.

Objectives:

Primary:

  1. To assess the efficacy of neoadjuvant therapy of bevacizumab by evaluating time to progression.
  2. Toxicities of therapy with bevacizumab in RCC.

Secondary:

Clinical:

  1. Response rate
  2. Duration of response
  3. Overall Survival

Preclinical:

  1. Serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and MMP-2, Interleukin 6 (IL-6), vascular endothelial growth factor (VEGF), and Basic Fibroblast Growth Factor (bFGF) pre- and post- therapy (optional studies).
  2. Tissue expression of Phospho-epidermal growth factor receptor (EGFR), VEGF, vessel count CD31/34, AKT and Phospho-AKT, mitogen-activated protein kinase (MAPK), transforming growth factor-alpha (TGF-alpha), phospho-STAT3 and TUNEL post therapy (optional studies).
  3. complementary DNA (cDNA) microarray analysis of tissue post-therapy (optional studies).
  4. Tissue expression of tumor infiltrating lymphocytes and tumor antigens
  5. Pathological response rate in primary tumor.
  6. To evaluate the Single Nucleotide Polymorphisms (SNP) patterns in nephrectomy specimens from patients participating in the study.

Condition Intervention Phase
Renal Cell Carcinoma
Kidney Cancer
Drug: Bevacizumab
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Neoadjuvant Clinical Trial to Evaluate the Efficacy of Recombinant Humanized Monoclonal Anti-VEGF Antibody rhuMab VEGF (Bevacizumab) for Renal Cell Carcinoma

Resource links provided by NLM:


Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Progression Free Survival (PFS) [ Time Frame: Up to 3 years (or until disease progression) ] [ Designated as safety issue: No ]
    Time to progression calculated from the start of the study drug to the first evidence of disease progression. Time to progression reported as PFS measured in months. Progression (or progressive disease) defined by Response Evaluation Criteria in Solid Tumors (RECIST) as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.


Secondary Outcome Measures:
  • Safety of Treatment [ Time Frame: Following 56 days treatment ] [ Designated as safety issue: Yes ]
    Safety measured by participant toxicities in therapy with bevacizumab for Renal Cell Carcinoma (RCC).


Enrollment: 52
Study Start Date: February 2005
Study Completion Date: August 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Bevacizumab
10 mg/kg intravenous (IV) Day 1 of 14-day cycle.
Drug: Bevacizumab
10 mg/kg IV on day 1 of each 14-day cycle.
Other Name: Avastin

  Show Detailed Description

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with histologically or cytologically confirmed clear cell metastatic RCC who are eligible for cytoreductive nephrectomy.
  • Patients must have measurable disease, defined as a lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) and measures greater than or equal to 20 mm with conventional techniques or greater than or equal to 10 mm with spiral computed tomography (CT) scan. This does not include primary tumors, which will be removed.
  • The Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 1
  • Female patients of childbearing potential (i.e. premenopausal, no hysterectomy) must have a normal plasma beta human chorionic gonadotropin (bHCG) within 24 hours prior to enrolling in the study due to the possible teratogenic effect. Patients with an elevated bHCG will undergo appropriate evaluation to rule out pregnancy (i.e. referral to Gyn service, pelvic ultrasound) and if pregnancy is ruled out and elevated bHCG is determined to be of tumor origin, patients will be permitted to proceed on study.
  • Patients of child fathering or childbearing potential must agree to practice a form of medically acceptable birth control while on study, i.e. condoms.
  • Patients must give written informed consent prior to initiation of therapy, in keeping with the policies of the institution. Patients with a history of major psychiatric illness must be judged able to fully understand the investigational nature of the study and the risks associated with the therapy. The only approved consent is attached to this protocol.
  • Patients must have ability to comply with study and/or follow-up procedures.
  • Patients must have adequate organ and marrow function within 14 days as defined below: absolute neutrophil count >/=1,500/micro platelets >/= 75,000/micro Hgb > 9.0 g/dL (may be transfused or receive epoetin alfa permitted) total bilirubin </= 2.0 mg/dL albumin > 3.0 g/dL serum creatinine </= 2.0 mg/dL aspartate aminotransferase (AST or SGOT) and/or alanine aminotransferase (ALT or SGPT) </= 2.5 * upper limit of normal (ULN), no liver metastases AST(SGOT) and/or ALT (SGPT) </= 5 * ULN, liver metastases present.

Exclusion Criteria:

  • Patients must not have organ allografts.
  • Patients must not have had major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, or anticipation of need for major surgical procedure during the course of the study (other than defined by protocol); or fine needle aspirations or core biopsies within 7 days prior to Day 0.
  • No prior malignancy is allowed, except for non-melanoma skin cancer, in situ carcinoma of any site, or other cancers for which the patient has been adequately treated and disease free for 5 years.
  • Patients must not have received any systemic anticancer therapy. Radiation therapy is allowed if >/= 2 weeks from study drug administration.
  • Patients must not be scheduled to receive another experimental drug while on this study. Patients are permitted to be on concomitant bisphosphonates and megestrol acetate.
  • Patients must not have a primary brain tumor (excluding meningiomas other benign lesions), any brain metastases, leptomeningeal disease, seizure disorders not controlled with standard medical therapy, or history of stroke within the past 5 years.
  • History of serious systemic disease, including myocardial infarction or unstable angina within the last 12 months, history of hypertensive crisis or hypertensive encephalopathy, uncontrolled hypertension (blood pressure of >140/90 mmHg on medication), New York Heart Association (NYHA) Grade II or greater congestive heart failure, unstable symptomatic arrhythmia requiring medication (subjects with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular tachycardia are eligible), significant vascular disease or symptomatic peripheral vascular disease.
  • Patients must not have history of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the subject at high risk from treatment complications.
  • Patients receiving any concomitant systemic therapy for renal cell cancer are excluded, but patients taking bisphosphonates and megestrol acetate are not excluded.
  • Patients must not require total parenteral nutrition with lipids.
  • Patients must not have significant proteinuria at baseline. Patients who are unexpectedly discovered to have greater than or equal to 1+ proteinuria on routine urinalysis at baseline should undergo a 24 hour urine collection, which must be an adequate collection and must demonstrate less than or equal to 1g of protein/24 hour to allow participation in the study.
  • Patients must not have clinical history of coagulopathy, bleeding diathesis or thrombosis.
  • Patients must not have a serious, nonhealing wound, ulcer, or bone fracture.
  • Pregnancy (positive pregnancy test) or lactation.
  • History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment.
  • Know hypersensitivity to any component of bevacizumab.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00113217

Locations
United States, Texas
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Genentech
Investigators
Principal Investigator: Eric Jonasch, MD M.D. Anderson Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT00113217     History of Changes
Other Study ID Numbers: 2003-0982
Study First Received: June 6, 2005
Results First Received: September 4, 2013
Last Updated: December 2, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by M.D. Anderson Cancer Center:
Renal Cell Carcinoma
Kidney Cancer
Bevacizumab
Avastin
RCC

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Renal Cell
Kidney Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Growth Inhibitors
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on April 16, 2014